Highlights of REGENXBIO - REGENXBIO is a leading clinical-stage biotechnology company - Utilizes AAV viral vectors from the proprietary gene delivery platform - Therapeutic areas include retinal, metabolic, and neurodegenerative diseases - $290 million in cash, cash equivalents and marketable securities as of September 30, 2020 REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Through a single administration, our gene therapy product candidates are designed to provide long-lasting effects, potentially significantly altering the course of the disease and delivering improved patient outcomes. Stock Symbol: RGNX RGNX Chart by TradingView REGENXBIO Platform Utilizes AAV viral vectors from...